Abstract: The present invention is directed to a method for the determination of a target nucleic acid using a special control nucleic acid, a method for the amplification of a partial sequence of said target nucleic acid using primers, a special control and a kit containing said control. The sequence of these control nucleic acids are at least in part parallel-complementary to the sequence of the target nucleic. These controls have similar properties as the target nucleic acid in hybridization and amplification methods, but can be well differentiated from the target nucleic acid by their different sequence.
Abstract: Overexpression of the gene, BAALC, in biological samples from a patient is prognostic for tumor aggressiveness and unfavorable patient outcome. The present invention provides polynucleotide primers and probes for assaying for overexpression of BAALC transcripts. Kits containing the primers and probes are also provided. Also provided are antibodies for assaying for overexpression of BAALC proteins as well as peptide immunogens for producing the anti-BAALC antibodies. The present invention also provides methods for characterizing acute myelogenous leukemia, chronic myelogenous leukemia and prostate cancer in a patient, base on detection of BAALC overexpression.
Type:
Grant
Filed:
November 12, 2002
Date of Patent:
November 25, 2008
Assignee:
The Ohio State University Research Foundation
Inventors:
Stephan Markus Tanner, Albert de la Chapelle
Abstract: An electrochemical detection system which specifically detects selected nucleic acid segments is described. The system utilizes biological probes such as nucleic acid or peptide nucleic acid probes which are complementary to and specifically hybridize with selected nucleic acid segments in order to generate a measurable current when an amperometric potential is applied. The electrochemical signal can be quantified.
Type:
Grant
Filed:
January 3, 2007
Date of Patent:
November 25, 2008
Assignee:
ESA Biosciences, Inc.
Inventors:
Robert W. Henkens, John P. O'Daly, Marek Wojciechowski, Honghua Zhang, Najih Naser, R. Michael Roe, Thomas N. Stewart, Deborah M. Thompson, Rebecca Sundseth, Steven E. Wegner
Abstract: The present invention provides methods for identifying individuals not at risk for developing myotonic dystrophy type 2 (DM2), and individuals that have or at risk for developing DM2. The present invention also provides isolated polynucleotides that include a repeat tract within intron 1 of the zinc finger protein 9.
Type:
Grant
Filed:
July 14, 2004
Date of Patent:
October 28, 2008
Assignee:
Regents of the University of Minnesota
Inventors:
Laura P. W. Ranum, John W. Day, Christina Liquori
Abstract: This disclosure provides for methods and reagents for rapid multiplex RPA reactions and improved methods for detection of multiplex RPA reaction products. In addition, the disclosure provides new methods for eliminating carryover contamination between RPA processes.
Type:
Grant
Filed:
July 25, 2006
Date of Patent:
October 14, 2008
Assignee:
ASM Scientific, Inc.
Inventors:
Olaf Piepenburg, Colin H. Williams, Niall A. Armes
Abstract: In one aspect the present invention provides methods of synthesizing a preparation of nucleic acid molecules, the methods comprising the steps of: (a) utilizing an RNA template to enzymatically synthesize a first DNA molecule that is complementary to at least 50 contiguous bases of the RNA template; (b) utilizing the first DNA molecule as a template to enzymatically synthesize a second DNA molecule, thereby forming a double-stranded DNA molecule wherein the first DNA molecule is hybridized to the second DNA molecule; (c) utilizing the first or second DNA molecule of the double-stranded DNA molecule as a template to enzymatically synthesize a first RNA molecule that is complementary to either the first DNA molecule or to the second DNA molecule; and (d) utilizing the first RNA molecule as a template to enzymatically synthesize a third DNA molecule that is complementary to the first RNA molecule.
Type:
Grant
Filed:
July 17, 2002
Date of Patent:
October 7, 2008
Assignee:
Rosetta Inpharmatics LLC
Inventors:
Daniel D. Shoemaker, Christopher D. Armour, Philip W. Garrett-Engele
Abstract: Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof.
Abstract: The present invention provides an organic conductor comprising a deoxyribonucleic acid (DNA) and an electric charge-donating material bonded to the deoxyribonucleic acid, and an organic conductor comprising at least two DNAs; and an electric charge-transfer substance bonding to each base of the two DNAs.
Abstract: The present invention provides a method for obtaining thermostable enzymes. The present invention also provides variants of DNA polymerase I from Thermus aquaticus. The present invention further provides methods of identifying mutant DNA polymerases having enhanced catalytic activity. The present invention also provides polynucleotides, expression systems, and host cells encoding the mutant DNA polymerases. Still further, the present invention provides a method to carry out reverse transcriptase-polymerase chain reaction (RT-PCR) and kits to facilitate the same.
Abstract: A set of primer pairs for amplifying a nucleic acid of an acetic acid-producing bacteria, each primer containing an oligonucleotide selected from the ackA gene region of the acetic acid-producing bacteria. The primers are particularly suitable for amplifying the nucleic acid of acetic acid-producing bacteria present in gas and oil production operations.
Abstract: Nucleic acid sequences for detecting the presence of nucleic acids, particularly mRNA, encoding human prostate-associated genetic markers encoding prostate-specific antigen (PSA), prostate specific membrane antigen (PSMA) or human kallikrein 2 (hK2) are disclosed. Preferred combinations of nucleic acid sequences amplifying and detecting the prostate-associated genetic markers RNA, used in methods that include amplification of the target sequences and detection of the amplified sequences are disclosed. Methods of detecting the presence of prostate-associated genetic marker nucleic acids, particularly mRNA, in a biological sample of non-prostate origin are disclosed.
Type:
Grant
Filed:
October 28, 2004
Date of Patent:
September 11, 2007
Assignee:
Gen-Probe Incorporated
Inventors:
Richard C. Harvey, Thomas J. Clark, Jr.
Abstract: A method of detecting reciprocal gene translocations by employing multiple probe sets which span the breakpoint regions and encompass regions on both sides of each breakpoint of the translocation on each chromosome involved in the translocation. Probe sets and diagnostic kits for the method are also disclosed.
Type:
Grant
Filed:
April 8, 2002
Date of Patent:
July 31, 2007
Assignee:
Ventana Medical Systems, Inc
Inventors:
Jeanne Dietz-Band, Wang-Ting Hsieh, John F. Connaughton
Abstract: The present invention provides an organic conductor comprising a deoxyribonucleic acid (DNA) and an electric charge-donating material bonded to the deoxyribonucleic acid, and an organic conductor comprising at least two DNAs; and an electric charge-transfer substance bonding to each base of the two DNAs.
Abstract: An assay is provided for nucleic acids that can be post-synthetically labeled, wherein modified nucleoside triphosphates are used that are more efficiently and specifically incorporated during nucleic acid synthesis than labeled nucleoside triphosphates. In a preferred embodiment, nucleoside ?-thiotriphosphates are utilized. Maleimide or iodoacetamide conjugating moieties can be attached post-synthetically. The conjugating moieties may include a reporter group. Also disclosed are new methods for detecting single nucleotide polymorphism.
Abstract: The present invention provides compositions comprising thermostable DNA polymerases derived from hyperthermophilic eubacteria. In particular, the present invention comprises thermostable DNA polymerases from the hyperthermophilic eubacterial species Thermoactinomyces vulgaris. The present invention also provides methods for utilizing naturally-occurring and non-naturally-occurring forms of T. vulgaris DNA polymerase in sequencing, reverse transcription, and amplification reactions.
Type:
Grant
Filed:
May 23, 2003
Date of Patent:
May 8, 2007
Assignee:
Promega Corporation
Inventors:
Trent Gu, Fen Huang, James Robert Hartnett
Abstract: The present invention is directed to a method for the determination of a target nucleic acid using a special control nucleic acid, a method for the amplification of a partial sequence of said target nucleic acid using primers, a special control and a kit containing said control. The sequence of these control nucleic acids are at least in part parallel-complementary to the sequence of the target nucleic. These controls have similar properties as the target nucleic acid in hybridization and amplification methods, but can be well differentiated from the target nucleic acid by their different sequence.
Abstract: The present invention is directed to a method for the determination of a target nucleic acid using a special control nucleic acid, a method for the amplification of a partial sequence of said target nucleic acid using primers, a special control and a kit containing said control. The sequence of these control nucleic acids are at least in part parallel-complementary to the sequence of the target nucleic. These controls have similar properties as the target nucleic acid in hybridization and amplification methods, but can be well differentiated from the target nucleic acid by their different sequence.
Abstract: The present invention provides a method for detecting a cellular proliferative disorder in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having said cellular proliferative, thereby detecting a cellular proliferative disorder in the subject.
Type:
Grant
Filed:
February 25, 2002
Date of Patent:
December 26, 2006
Assignee:
The Johns Hopkins University School of Medicine